Guardant Health Inc GH Profile, Company FAQs & Facts, Industry, Sector, Employee Strength

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year.

Shares fell about 10% that day, implying investor concern about the implications of the study closure on the firm’s prospects. However, after hearing management’s explanation for the study closure and reviewing the assumptions in our model, we expect to trim our forecasts only minimally, with no material impact on our $63 fair value estimate. With the significant stock price decline, shares still look undervalued to us. The Barchart stock market infographic Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.

• Market cap, also known as market capitalization, is the total market value of a company.
• After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study.
• The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research.
• It’s calculated by dividing the current share price by the earnings per share (or EPS).

On average, they predict the company’s share price to reach $55.44 in the next twelve months. This suggests a possible upside of 87.0% from the stock’s current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts. 15 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Guardant Health in the last twelve months. The consensus among Wall Street analysts is that investors should “buy” GH shares.

The Wall Street Journal

USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm … Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisions for patients with advanced solid cancers   The liqui… 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com.

According to 14 analysts, the average rating for GH stock is “Strong Buy.” The 12-month stock price forecast is $54.79, which is an increase of 84.85% from the latest price. GH, +2.46% shares fell in the extended session Monday after the cancer testing company announced a secondary offering of its stock. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. Style is an investment factor that has a meaningful impact on investment risk and returns.

An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, GH info will be updated daily in your Zacks.com Portfolio Tracker – also free. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business.

Investor Email Alerts

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company was incorporated in 2011 and is headquartered in Palo Alto, California. Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics.

Stock Money Flow

The technique has proven to be very useful for finding positive surprises. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

GH Related stocks

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. These companies’ growth stories still have plenty of exciting chapters ahead. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. Additionally, Guardant offers research development services. In 2022, the United States accounted for 94% of revenue, and other markets the remaining 6%.

Dow Jones Network

It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Guardant Health Inc 52 week low is $20.67 as of October 01, 2023.

These returns cover a period from January 1, 1988 through September 4, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Liquid biopsy is at the core of our mission to conquer cancer with data.

Helmy Eltoukhy has an approval rating of 95% among the company’s employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Guardant Health updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company issued revenue guidance of $545.00 million-$550.00 million, compared to the consensus revenue estimate of $541.39 million. EBITDA is a widely used measure of corporate profitability.

Style is calculated by combining value and growth scores, which are first individually calculated. Guardant Health’s stock was trading at $27.20 on January 1st, 2023. Since then, GH shares have increased by 9.0% and is now trading at $29.64. USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet value investing published an analysis back in April 2023, showing a rising incidence of pancreatic cancer… /PRNewswire/ — USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in… The precision oncology leader benefited from a pair of positive analyst notes this week.

After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, acciones de uber pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 15 brokerages have issued 1 year price targets for Guardant Health’s stock. Their GH share price forecasts range from $34.00 to $88.00.